Evaluating the risk of phospholipidosis using a new multidisciplinary pipeline approach

European Journal of Medicinal Chemistry

Volumn 92, Issue , 2015, Pages 49-63

  Goracci, Laura ^a   Buratta, Sandra ^a   Urbanelli, Lorena ^a   Ferrara, Giuseppina ^a   Di Guida, Riccardo ^a   Emiliani, Carla ^a   Cross, Simon ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Molecular Discovery Limited   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS(2 CHLOROBENZYLAMINOMETHYL)CYCLOHEXANE; AMIODARONE; AMPHOPHILE; BETA N ACETYLHEXOSAMINIDASE; CATIONIC AMPHIPHILIC DRUG; IMIPRAMINE; LIDOCAINE; LYSOSOME ENZYME; MECLOZINE; PHOSPHATIDYLCHOLINE; QUINUCLIDINE; UNCLASSIFIED DRUG; CATION; PHOSPHOLIPID; SURFACTANT;

ARTICLE; CELL VIABILITY; COMPUTER MODEL; CYTOTOXICITY; DRUG SCREENING; ENZYME ACTIVITY; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPIDOSIS; MOLECULAR INTERACTION; PHARMACOPHORE; PHOSPHOLIPIDOSIS PHORE; PREDICTION; RISK ASSESSMENT; TOXICOLOGY; TOXICOPHORE; TRANSMISSION ELECTRON MICROSCOPY; BIOSYNTHESIS; BLOOD;

CATIONS; HUMANS; PHOSPHOLIPIDS; RISK ASSESSMENT; SURFACE-ACTIVE AGENTS;

EID: 84936847575     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.12.028     Document Type: Article

References (50)

1. W.H. Halliwell, Cationic amphiphilic drug-induced phospholipidosis, Toxicol. Pathol. 25 (1997) 53-60.
2. M.J. Reasor, K.L. Hastings, R.G. Ulrich, Drug-induced phospholipidosis: issues and future directions, Expert. Opin. Drug Saf. 5 (2006) 567-583.
3. L.A. Chatman, D. Morton, T.O. Johnson, S.D. Anway, A strategy for risk management of drug-induced phospholipidosis, Toxicol. Pathol. 37 (2009) 997-1005.
4. S.H. Slavov, J.G. Wilkes, D.A. Buzatu, N.L. Kruhlak, J.M. Willard, J.P. Hanig, R.D. Beger, Computational identification of a phospholipidosis toxicophore using 13C and 15N NMR-distance based fingerprints, Bioorg. Med. Chem. (2014), http://dx.doi.org/10.1016/j.bmc.2014.08.021.
5. J.P. Ploemen, J. Kelder, T. Hafmans, H. van de Sandt, J.A. van Burgsteden, P.J. Saleminki, E. van Esch, Use of physicochemical calculation of pKa and CLogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines, Exp. Toxicol. Pathol. 55 (2004) 347-355.
6. S.S. Choi, J.S. Kim, L.G. Valerio, N. Sadrieh, In silico modeling to predict druginduced phospholipidosis, Toxicol. Appl. Pharmacol. 269 (2013) 195-204.
7. H. Sun, M. Xia, S.A. Shahane, A. Jadhav, C.P. Austin, R. Huang, Are hERG channel blockers also phospholipidosis inducers? Bioorg. Med. Chem. Lett. 23 (2013) 4587-4590.
8. T. Nonoyama, R. Fukuda, Drug-induced phospholipidosis-pathological aspects and its prediction, J. Toxicol. Pathol. 21 (2008) 9-24.
9. F.M. van de Water, J. Havinga, W.T. Ravesloot, G.J. Horbach, W.G. Schoonen, High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis, Toxicol. In Vitro 25 (2011) 1870-1882.
10. A. Casartelli, A. Lanzoni, R. Comelli, F. Crivellente, R. Defazio, R. Dorigatti, N. Fasdelli, I. Faustinelli, S. Pagliarusco, M. Tontodonati, P. Cristofori, A novel and integrated approach for the identification and characterization of druginduced cardiac toxicity in the dog, Toxicol. Pathol. 39 (2011) 361-371.
11. P. Vitovic, J.M. Alakoskela, P.K. Kinnunen, Assessment of drug-lipid complex formation by a high-throughput Langmuir-balance and correlation to phospholipidosis, J. Med. Chem. 51 (2008) 1842-1848.
12. L. Zhou, G. Geraci, S. Hess, L. Yang, J. Wang, U. Argikar, Predicting phospholipidosis: a fluorescence noncell based in vitro assay for the determination of drug-phospholipid complex formation in early drug discovery, Anal. Chem. 83 (2011) 6980-6987.
13. K. Tomizawa, K. Sugano, H. Yamada, I. Horii, Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential, J. Toxicol. Sci. 31 (2006) 315-324.
14. U.M. Hanumegowda, G. Wenke, A. Regueiro-Ren, R. Yordanova, J.P. Corradi, S.P. Adams, Phospholidosis as a function of basicity, liphophilicity and volume of distribution of compound, Chem. Res. Toxicol. 23 (2010) 749-755.
15. H. Fischer, E.A. Atzpodien, M. Csato, L. Doessegger, B. Lenz, G. Schmitt, T. Singer, In silico assay for assessing phospholipidosis potential of small drug like molecules: training, validation, and refinement using several data sets, J. Med. Chem. 55 (2012) 126-139.
16. R. Lowe, R.C. Glen, J.B. Mitchell, Predicting phospholipidosis using machine learning, Mol. Pharmac. 7 (2010) 1708-1714.
17. M. Baroni, G. Cruciani, S. Sciabola, F. Perruccio, J.S. Mason, A common reference framework for analyzing/comparing proteins and ligands. Fingerprints for ligands and Proteins (FLAP): theory and application, J. Chem. Inf. Model. 47 (2007) 279-294.
18. S. Cross, M. Baroni, L. Goracci, G. Cruciani, GRID-based three-dimensional pharmacophores I: FLAP pharm, a novel approach for pharmacophore elucidation, J. Chem. Inf. Model. 52 (2012) 2587-2598.
19. S. Cross, F. Ortuso, M. Baroni, G. Costa, S. Distinto, F. Moraca, S. Alcaro, G. Cruciani, GRID-based three-dimensional pharmacophores II: pharmbench, a benchmark data set for evaluating pharmacophore Elucidation methods, J. Chem. Inf. Model. 52 (2012) 2599-2608.
20. L. Goracci, M. Ceccarelli, D. Bonelli, G. Cruciani, Modeling phospholipidosis induction: reliability and warnings, J. Chem. Inf. Model 53 (2013) 1436-1446.
21. R. Mannhold, G. Berellini, E. Carosati, P. Benedetti, Use of MIF-based volsurf descriptors in physicochemical and pharmacokinetic studies, in: G. Cruciani (Ed.), Molecular Interaction Fields: Applications in Drug Discovery and ADME Prediction vol. 27, Wiley-VCH, New York, 2006, pp. 173-196.
22. D.J. Pelletier, D. Gehlhaar, A. Tilloy-Ellul, T.O. Johnson, N. Greene, Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential, J. Chem. Inf. Model. 47 (2007) 1196-1205.
23. O. Ivanciuc, Weka machine learning for predicting the phospholipidosis inducing potential, Curr. Top. Med. Chem. 8 (2008) 1691-1709.
24. H.T. Yudate, T. Kai, M. Aoki, Y. Minowa, T. Yamada, T. Kimura, A. Ono, H. Yamada, Y. Ohno, T. Urushidani, Identification of a novel set of biomarkers for evaluating phospholipidosis-inducing potential of compounds using rat liver microarray data measured 24-h after single dose administration, Toxicology 295 (2012) 1-7.
25. F. Milletti, L. Storchi, L. Goracci, S. Bendels, B. Wagner, M. Kansy, G. Cruciani, Extending pKa prediction accuracy: high-throughput pKa measurements to understand pKa modulation of new chemical series, Eur. J. Med. Chem. 45 (2010) 4270-4279.
26. S. Nadanaciva, S. Lu, D.F. Gebhard, B.A. Jessen, W.D. Pennie, Y. Will, A high content screening assay for identifying lysosomotropic compounds, Toxicol. In Vitro 25 (2011) 715-723.
27. F.B. Baell, G.A. Holloway, New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays, J. Med. Chem. 53 (2010) 2719-2740.
28. S. Miyamoto, A. Matsumoto, I. Mori, A. Horinouchi, Relationship between in vitro phospholipidosis assay using HepG2 cells and 2-week toxicity studies in rats, Toxicol. Mech. Methods 19 (2009) 477-485.
29. S. Park, Y.J. Choi, B.H. Lee, In vitro validation of drug-induced phospholipidosis, J. Toxicol. Sci. 37 (2012) 261-267.
30. E.E. Golli-Bennour, A. Bouslimi, O. Zouaoui, S. Nouira, A. Achour, H. Bacha, Cytotoxicity effects of amiodarone on cultured cells, Exp. Toxicol. Pathol. 64 (2012) 425-430.
31. H. Fujimura, E. Dekura, M. Kurabe, N. Shimazu, M. Koitabashi, W. Toriumi, Cell-based fluorescence assay for evaluation of new-drugs potential for phospholipidosis in an early stage of drug development, Exp. Toxicol. Pathol. 58 (2007) 375-382.
32. T. Kasahara, K. Tomita, H. Murano, T. Harada, K. Tsubakimoto, T. Ogihara, S. Ohnishi, C. Kakinuma, Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential, Toxicol. Sci. 90 (2006) 133-141.
33. A. Casartelli, M. Bonato, P. Cristofori, F. Crivellente, G. Dal Negro, I. Masotto, C. Mutinelli, K. Valko, V. Bonfante, A cell based approach for the early assessment of phospholipidogenic potential in pharmacological research and drug development, Cell Biol. Toxicol. 19 (2003) 161-176.
34. H. Sawada, K. Takami, S. Asahi, A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system, Toxicol. Sci. 83 (2005) 282-292.
35. F. Atienzar, H. Gerets, S. Dufrane, K. Tilmant, M. Cornet, S. Dhalluin, B. Ruty, G. Rose, M. Canning, Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells, Toxicol. Sci. 96 (2007) 101-114.
36. P. Nioi, B.K. Perry, E.J. Wang, Y.Z. Gu, R.D. Snyder, In vitro detection of druginduced phospholipidosis using gene expression and fluorescent phospholipid based methodologies, Toxicol. Sci. 99 (2007) 162-173.
37. A. Baritussio, S. Marzini, M. Agostini, A. Alberti, C. Cimenti, D. Bruttomesso, E. Manzato, D. Quaglino, A. Pettenazzo, Amiodarone inhibits lung degradation of SP-A and perturbs the distribution of lysosomal enzymes, Am. J. Physiol. Lung Cell. Mol. Physiol. 281 (2001) L1189eL1199.
38. K. Ikeda, M. Hirayama, Y. Hirota, E. Asa, J. Seki, Y. Tanaka, Drug-induced phospholipidosis is caused by blockade of mannose 6-phosphate receptormediated targeting of lysosomal enzymes, Biochem. Biophys. Res. Commun. 377 (2008) 268-274.
39. P. Schneider, T.A. Korolenko, U. Busch, A review of drug-induced lysosomal disorders of the liver in man and laboratory animals, Microsc. Res. Tech. 36 (1997) 253-275.
40. J. Fischer, H. Lüllmann, R. Lüllmann-Rauch, Drug-induced lysosomal storage of sulphated glycosaminoglycans, Gen. Pharmacol. 27 (1996) 1317-1324.
41. R. Lullmann-Rauch, R. Pods, B. Von Witzendorff, Tilorone-induced lysosomal storage of sulphatedglycosaminoglycans can be separated from tiloroneinduced enhancement of lysosomal enzyme secretion, Biochem. Pharmacol. 49 (1995) 1223-1233.
42. V.K. Aggarwal, I. Emme, S.Y. Fulford, Correlation between pK(a) and reactivity of quinuclidine-based catalysts in the Baylis-Hillman reaction: discovery of quinuclidine as optimum catalyst leading to substantial enhancement of scope, J. Org. Chem. 68 (2003) 692-700.
43. M. Jagel, R. Lüllmann-Rauch, Lipidosis-like alterations in cultured macrophages exposed to local anaesthetics, Arch. Toxicol. 55 (1984) 229-232.
44. A.M. Orogo, S.S. Choi, B.L. Minnier, N.L. Kruhlak, Construction and Consensus Performance of (Q)SAR models for predicting phospholipidosis using a dataset of 743 compounds, Mol. Inf. 31 (2012) 725-739.
45. G. Muratore, L. Goracci, B. Mercorelli, A. Foeglein, P. Digard, G. Cruciani, G. Palù, A. Loregian, Small molecule inhibitors of influenza A and B viruses that act by disrupting subunit interactions of the viral polymerase, Proc. Natl. Acad. Sci. U. S. A. 109 (2012) 6247-6252.
46. F. Spyrakis, R. Singh, P. Cozzini, B. Campanini, E. Salsi, P. Felici, S. Raboni, P. Benedetti, G. Cruciani, G.E. Kellogg, P.F. Cook, A. Mozzarelli, Isozyme-specific ligands for O-acetylserinesulfhydrylase, a novel antibiotic target, PLoS One 8 (2013) e77558.
47. F. Sirci, L. Goracci, D. Rodriguez, J. van Muijlwijk-Koezen, H. Gutierrez-de-Teran, R. Mannhold, Ligand-, structure-and pharmacophore-based molecular fingerprints: a case study on adenosine A1, A2A, A2B, and A3 receptor antagonists, J. Comput. Aided Mol. Des. 26 (2012) 1247-1266.
48. G. Cruciani, P. Crivori, P.A. Carrupt, B. Testa, Molecular Fields in Quantitative structure-Permeation relationships: the VolSurf approach, J. Mol. Struct. THEOCHEM 503 (2000) 17-30.
49. E. Borenfreund, J.A. Puerner, Toxicity determined in vitro by morphological alterations and neutral red absorption, Toxicol. Lett. 24 (1985) 119-124.
50. A. Magini, A. Polchi, B. Tancini, L. Urbanelli, A. Hasilik, C. Emiliani, Glycohydrolases b-hexosaminidase and b-galactosidase are associated with lipid microdomains of Jurkat T-lymphocytes, Biochimie 94 (2012) 684-694.